Browse News
Filter News
Found 171 articles
-
YourChoice Therapeutics Scientific Advisory Board member updates phase 1a study for male birth control candidate at ACS Spring 24
3/19/2024
YourChoice Therapeutics, a San Francisco biotech startup developing the first hormone-free male birth control pill, announced today that Gunda Georg, YCT-529’s co-inventor, provided an update on its phase 1a clinical study for the first hormone-free male birth control pill, YCT-529, at the American Chemical Society (ACS) 2024 Spring Meeting.
-
South Rampart Pharma Successfully Completes Phase 1 Study and Expands Phase 2 Plans to Include Neuropathic and Acute Pain Trials
1/2/2024
South Rampart Pharma, Inc. announced today that it has successfully completed a Phase 1 trial (NCT05484414).
-
Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC
11/27/2023
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced that it has finalized the development of an updated formulation of fostrox, suitable for commercial manufacture.
-
Ergomed strongly positioned for future growth in new partnership with Permira
11/14/2023
Ergomed plc and Permira Advisers LLP, are pleased to announce the completion of the acquisition of Ergomed by funds advised by Permira for £703.1 million.
-
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360
10/18/2023
Ensysce Biosciences, Inc. today announced Dr. Dolly Jacob, Director Integrated Development Services of Quotient Sciences, will present the collaborative work of Ensysce and Quotient Sciences in a poster.
-
Wren Laboratories’ new molecular diagnostic predicts patient response to Peptide Receptor Radionuclide Therapy with unprecedented accuracy
9/25/2023
Neuroendocrine Cancer treatment response test, PPQ, delivers 96% accuracy
-
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
7/24/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase 2/3 CAPELLA trial.
-
Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
6/27/2023
Ensysce Biosciences, Inc. today announced that the company will be providing a poster presentation at the upcoming CRS (Controlled Release Society) 2023 Annual Meeting & Expo.
-
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single-Ascending Dose and Multiple-Ascending Dose Trial of Adjunctive EVX-101 in Healthy Volunteers Treated With a First-Line Antidepressant
4/10/2023
Evecxia Therapeutics, Inc. today announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram.
-
Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ) - March 30, 2023
3/30/2023
The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting, to be held on Tuesday, 9 May 2023 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
-
Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
3/30/2023
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2022.
-
Preliminary results 2022 of Sartorius Stedim Biotech
1/26/2023
Following extraordinary growth in 2020 and 2021, Sartorius Stedim Biotech, a leading partner of the biopharma industry, again outperformed the market in fiscal 2022.
-
Sartorius with clear double-digit growth in fiscal 2022
1/26/2023
Following extraordinary growth in 2020 and 2021, the life science group Sartorius again outperformed the market in fiscal 2022, achieving its targets for sales revenue and profitability.
-
Ensysce Biosciences Issues 2023 Shareholder Letter
1/11/2023
Ensysce Biosciences, Inc. today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick.
-
LEX Diagnostics Appoints Ed Farrell as Chief Executive Officer
1/11/2023
LEX Diagnostics announces the appointment of Ed Farrell as its new Chief Executive Officer.
-
Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection
12/19/2022
Ensysce Biosciences, Inc. today announced data demonstrating the overdose protection of its drug product, PF614-MPAR from the clinical study being conducted in Healthy Subjects by Dr. Maria Bermudez MD, at Quotient Sciences, Miami, Florida.
-
Lysogene’s investigational gene therapy LYS-SAF302 failed to meet its primary and key secondary efficacy endpoints in mucopolysaccharidosis type IIIA.
-
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
11/18/2022
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.
-
Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth
11/10/2022
Novozymes, the world leader in biological solutions, and LinusBio, a leader in precision exposome sequencing, announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial.
-
Sannova Appoints Jason Apter as CEO and Stephen Unger as CFO
10/26/2022
Sannova Analytical, LLC (“Sannova”), a leading contract research organization (“CRO”) that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer.